Form 4: Amylyx Pharmaceuticals Director Acquires Stock Options

Karen Firestone, a Director at Amylyx Pharmaceuticals, acquired 24,372 stock options with an exercise price of $14.31.

Summary

• Karen Firestone, a Director at Amylyx Pharmaceuticals, Inc. (AMLX), acquired 24,372 stock options on June 4, 2026.
• The exercise price for these options is $14.31 per share.
• These options are exercisable and expire on June 3, 2036.
• The underlying securities are 24,372 shares of Common Stock.
• The options are subject to vesting conditions, with full vesting occurring on the earlier of June 4, 2027, or the next annual meeting, contingent on continuous service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard stock option grant to a director, indicating confidence but not a significant event.

Positives

• Director Karen Firestone has acquired a significant number of stock options, indicating a commitment to the company's future performance.
• The acquisition of options at an exercise price of $14.31 suggests a belief in future stock price appreciation above this level.

Risks

• The vesting of the stock options is contingent on the Reporting Person's continuous service to the Issuer, meaning any departure before the vesting date could result in forfeiture.
• The value of the stock options is directly tied to the future performance and stock price of Amylyx Pharmaceuticals.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future performance, as the value of these options is directly linked to stock price appreciation.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology and pharmaceutical sectors as a means to incentivize long-term performance and align management interests with shareholders, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns management incentives with shareholder interests, potentially driving long-term value creation.
• Employees: May signal confidence from the board in the company's future, potentially boosting morale.
• Management: Karen Firestone has a vested interest in the company's stock performance.

Next Steps

• The stock options will vest according to the specified schedule, contingent on Karen Firestone's continued employment with Amylyx Pharmaceuticals.
• The options can be exercised by the Reporting Person on or after their vesting dates, up until the expiration date.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, Securities Exchange Act